ORAL CIPROFLOXACIN THERAPY OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA
Open Access
- 1 April 1986
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 327 (8485) , 819-822
- https://doi.org/10.1016/s0140-6736(86)90937-2
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteersAntimicrobial Agents and Chemotherapy, 1985
- Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disksJournal of Clinical Microbiology, 1985
- The Pharmacokinetics and Serum and Urine Bactericidal Activity of CiprofloxacinThe Journal of Clinical Pharmacology, 1985
- Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosaThe American Journal of Medicine, 1985
- Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteersAntimicrobial Agents and Chemotherapy, 1984
- Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- Pharmacokinetics and tissue penetration of ciprofloxacinAntimicrobial Agents and Chemotherapy, 1983
- In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprimAntimicrobial Agents and Chemotherapy, 1983
- In vitro activity of ciprofloxacin, norfloxacin and nalidixic acidEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983